The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis

BACKGROUND: Treatment choice for metastatic renal cell carcinoma (mRCC) patients is still based on baseline clinical and laboratory factors. METHODS: By a pre-specified analysis of the Meet-URO 15 multicentric retrospective study enrolling 571 pretreated mRCC patients receiving nivolumab, baseline a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebuzzi, Sara Elena, Signori, Alessio, Stellato, Marco, Santini, Daniele, Maruzzo, Marco, De Giorgi, Ugo, Pedrazzoli, Paolo, Galli, Luca, Zucali, Paolo Andrea, Fantinel, Emanuela, Carella, Claudia, Procopio, Giuseppe, Milella, Michele, Boccardo, Francesco, Fratino, Lucia, Sabbatini, Roberto, Ricotta, Riccardo, Panni, Stefano, Massari, Francesco, Sorarù, Mariella, Santoni, Matteo, Cortellini, Alessio, Prati, Veronica, Soto Parra, Hector Josè, Atzori, Francesco, Di Napoli, Marilena, Caffo, Orazio, Messina, Marco, Morelli, Franco, Prati, Giuseppe, Nolè, Franco, Vignani, Francesca, Cavo, Alessia, Roviello, Giandomenico, Llaja Obispo, Miguel Angel, Porta, Camillo, Buti, Sebastiano, Fornarini, Giuseppe, Banna, Giuseppe Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541611/
https://www.ncbi.nlm.nih.gov/pubmed/36212433
http://dx.doi.org/10.3389/fonc.2022.955501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541611/
https://www.ncbi.nlm.nih.gov/pubmed/36212433
http://dx.doi.org/10.3389/fonc.2022.955501

Ejemplares similares